Understanding the ocular accumulation of mefuparib and its N-dealkylation metabolite: Pharmacokinetics, melanin affinity, and cellular disposition
Experimental Eye Research · 2026
DOI: 10.1016/j.exer.2026.111155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026. Verfasst von Yan Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Shanghai Institute of Materia Medica, Chinese Academy of Scienc…. Hauptthemen laut MEDLINE: Melanins, Retinal Pigment Epithelium, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Mefuparib, a novel poly (ADP-ribose) polymerase inhibitor (PARP), is primarily utilized for treating various advanced or metastatic malignant tumors. Previous research has indicated that mefuparib-related compounds accumulate notably in the eyes. However, the precise mechanism and components of this accumulation remain unclear. Using quantitative whole-body autoradiography (QWBA), cell uptake and release models, and in vitro melanin binding experiments to explore the accumulation characteristics of mefuparib and its N-dealkylation metabolite M8 in the eye. Results showed the area under the curve (AUC0-48h) of mefuparib in Long-Evans (LE) rats was 58.1 times higher than in Sprague-Dawley (SD) rats, with a longer half-life. Conversely, M8 had a lower (AUC0-48h) in LE rats. This indicates the main substance accumulated in the eyes is mefuparib, and the accumulation site is the pigment membrane of LE rats. The uptake of mefuparib by Retinal Pigment Epithelium (RPE) cells was 2.81-4.92 times that of Adult Retinal Pigment Epithelial-19 (ARPE-19) cells, and the release within 24 h was only 30.5%. Its melanin binding parameter Bmax (451 ± 3.15 nmol/mg) was significantly higher than that of M8 (120 ± 6.43 nmol/mg). In conclusion, the high uptake, low release and strong melanin binding capacity of mefuparib jointly lead to its intraocular accumulation, providing data support for the subsequent optimization of compound structure to reduce ocular accumulation or offering new directions for the development of new ocular treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
- School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
- Convalife (Shanghai) Co. Ltd, Shanghai, 201203, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. Electronic address: yujinghua2@simm.ac.cn.
- School of Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. Electronic address: xxdiao@simm.ac.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Peng, Y., Xiao, B., Wang, F., Shen, X., Huang, J., Yu, J., & Diao, X. (2026). Understanding the ocular accumulation of mefuparib and its N-dealkylation metabolite: Pharmacokinetics, melanin affinity, and cellular disposition. Experimental Eye Research. https://doi.org/10.1016/j.exer.2026.111155
Vancouver
Peng Y, Xiao B, Wang F, Shen X, Huang J, Yu J, et al. Understanding the ocular accumulation of mefuparib and its N-dealkylation metabolite: Pharmacokinetics, melanin affinity, and cellular disposition. Experimental Eye Research. 2026. doi:10.1016/j.exer.2026.111155
BibTeX
@article{Peng2026,
author = {Peng, Yan and Xiao, Bo and Wang, Feiyu and Shen, Xiaokun and Huang, Jinwen and Yu, Jinghua and Diao, Xingxing},
title = {Understanding the ocular accumulation of mefuparib and its N-dealkylation metabolite: Pharmacokinetics, melanin affinity, and cellular disposition},
journal = {Experimental Eye Research},
year = {2026},
doi = {10.1016/j.exer.2026.111155}
}
EUVIMED